Detailed price information for Pacira Pharm Inc (PCRX-Q) from The Globe and Mail including charting and trades.
Total revenues of $167.1 million Net product sales of $132.4 million for EXPAREL, $25.8 million for ZILRETTA, and $5.0 million for iovera° Net income of $9.0 million, or $0.19 per share (basic and ...
See “Non-GAAP Financial Information” below. “We entered 2025 sharply focused on our 5x30 strategy and our transition into an innovative biopharmaceutical organization,” said Frank D. Lee, chief ...
BRISBANE, Calif., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the ...
In 2021, it was estimated that about 23% of adults living in Las Vegas, NV had arthritis. Osteoarthritis (OA), the most common form of arthritis, affects millions of people worldwide. OA symptoms can ...
Pacira BioSciences PCRX announced results from a pilot study evaluating the unique therapeutic approach of its iovera system compared to radiofrequency ablation (RFA) for chronic low back pain (CLBP).
-- Record-high EXPAREL sales driven by volume growth of 7 percent, marking strongest fourth quarter performance in three years-- BRISBANE, Calif., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback